DRUG

namilumab

7 hypotheses across 2 therapeutic domains

ALL HYPOTHESES

Repurposing candidates for namilumab

Multiple sclerosis 4

Mediator Outcome Score Tier Lit. status Trial
GM-CSF relapsing-remitting multiple sclerosis 0.208 Mid novel signal none
GM-CSF autoimmune diseases 0.208 Mid partial evidence completed
GM-CSF multiple sclerosis 0.208 Mid novel signal none
GM-CSF disability accumulation 0.208 Mid novel signal none

Pancreatic cancer 3

Mediator Outcome Score Tier Lit. status Trial
GM-CSF metastatic PDAC 0.208 Mid novel signal none
GM-CSF cachexia 0.208 Mid novel signal none
GM-CSF poor prognosis 0.208 Mid novel signal none

Clinical trials

9 registered trials for namilumab

Source: ClinicalTrials.gov

← All drugs